# Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

> **NCT02991859** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 56 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone furoate (FF) Dry Powder Inhaler
- **DRUG:** Fluticasone propionate (FP) Dry Powder Inhaler
- **DRUG:** Budesonide (BUD) Turbuhaler
- **DRUG:** Placebo (ELLIPTA or DISKUS)

## Key facts

- **NCT ID:** NCT02991859
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-09
- **Primary completion:** 2018-12-20
- **Final completion:** 2018-12-20
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02991859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02991859, "Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02991859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*